Shop Medical Lab Equipment
Abinscience InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) (MS870039-100ug)
Overview
| Catalog No. | MS870039-100ug |
|---|---|
| Description | Abinscience InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14)[RMP1-14] (MS870039-100ug) is a rat monoclonal
antibody detecting Programmed cell death protein 1
in in vivo blocking of PD-1/PD-L signaling. Suitable for Mouse.
|
| Species reactivity | Mouse |
| Applications | in vivo blocking of PD-1/PD-L signaling |
| Host species | Rat |
| Isotype | IgG2a, kappa |
| Clone ID | RMP1-14 |
| Clonality | Monoclonal |
| Target | Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1 |
| Endotoxin level | <1 EU/mg |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q02242 |
| RRID | InVivo Plus Anti-Mouse PD-1 Antibody(RMP1-14) (abinScience Cat# MS870039, RRID:AB_3722748) |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Nishimura, H. et al. (1999) Immunity 11, 141-51. PMID: 10485649
2. Nishimura, H. et al. (2001) Science (New York, N.Y.) 291, 319-22. PMID: 11209085
3. Okazaki, T. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 13866-71. PMID: 11698646
4. Okazaki, T. et al. (2011) The Journal of experimental medicine 208, 395-407. PMID: 21300912
5. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
6. Latchman, Y. et al. (2001) Nature immunology 2, 261-8. PMID: 11224527
7. Lin, DY. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 3011-6. PMID: 18287011
8. Lázár-Molnár, E. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 10483-8. PMID: 18641123
9. Yokosuka, T. et al. (2012) The Journal of experimental medicine 209, 1201-17. PMID: 22641383
|
| Note | For research use only. |
Images
SDS-PAGE for InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14).
Mice treatment with RMP1-14 significantly reduced tumor growth compared with the Rat IgG2a isotype control ( RF533109), as shown by lower tumor volumes during the observation period.
Datasheets
InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14).pdf